IL17A and psoriasis: In particular, the most suitable candidates for extended dosing are those achieving complete skin clearance (Psoriasis Area and Severity Index = 0, body surface area = 0%) at week 20 of treatment who exhibit concomitant PsA at the baseline, are bio-naïve, or have not received an IL-17 inhibitor as previous biological therapy.